Document:

Employment Agreement between Leslie Hudson, Ph.D and Nabi

 Exhibit 10.11 
 Nabi Biopharmaceuticals 
 5800 Park of Commerce Boulevard, N.W. 
 Boca Raton, Florida 33487 
 Employment Agreement 
 Executed October 15, 2007 
 Effective as of August 16, 2007 
 Leslie Hudson, Ph.D 
 Chief Executive Officer 
 Nabi Biopharmaceuticals 
 5800 Park of Commerce Boulevard, N.W. 
 Boca Raton, Florida 33487 

Dear Dr. Hudson: 
 Commencing immediately after the conclusion on
August 16, 2007 (the “Effective Date”) of your successful interim six-month term as President and Chief Executive Officer of Nabi Biopharmaceuticals (“Nabi”), at Nabi’s request, you have agreed to continue to serve on
an interim basis as President and Chief Executive Officer of Nabi. This Agreement sets forth the terms of such employment. 
 1. TERM:
You will serve as Nabi’s President and Chief Executive Officer for a period beginning on the Effective Date and ending on February 16, 2008 (the “Expiration Date”), unless your employment is sooner terminated as provided below
(the “Employment Period”). 
 2. SALARY: Your salary will be $40,000 per month, payable bi-weekly during the Employment Period
and pro rated for any partial month during the Employment Period. You will not receive director fees during the Employment Period. 
 3. BONUS:

 (A) Nabi will pay you a cash bonus of $100,000 upon the execution of this Agreement. 
 (B) In addition, Nabi will pay you a cash bonus of $50,000 immediately (and in all cases prior to March 15, 2008) upon the earlier of (i) the Expiration Date provided you are will employed on that date,
(ii) Nabi’s termination of your employment without Cause and (iii) the date on which a new Chief Executive Officer commences employment in such position, provided that your employment has not been terminated by Nabi for Cause (such
earliest date being referred to herein as the “Payment Date”). In the event of your death or the termination by Nabi of your employment pursuant to Section 7(B) because of your disability, Nabi will pay you a prorated portion of the
$50,000 bonus based upon the number of days elapsed in the Employment Period through the date of the termination of your employment. 

 (C) Finally, Nabi will pay you an incentive cash bonus (the “Incentive Bonus”) of up to $190,000 equal to
$190,000 multiplied by the aggregate Weighting Percentage of the Performance Goals set forth on Exhibit A achieved during the Employment Period. The amount of the Incentive Bonus will be determined and paid within fifteen (15) days
of the Payment Date, provided that if such Incentive Bonus is due on a Payment Date prior to the Expiration Date, it will be paid in the full amount of $190,000. In the event of your death or the termination by Nabi of your employment pursuant to
Section 7(B) because of your disability, Nabi will pay you a prorated portion of the Incentive Bonus based upon the number of days elapsed in the Employment Period through the date of the termination of your employment and assuming the
achievement of each of the Performance Goals. 
 4. EQUITY RELATED COMPENSATION: 
 (A) On the date this Agreement is executed by the parties, Nabi will grant to you two awards of restricted shares of Nabi common stock (the “Restricted Stock”)
pursuant to the terms of Nabi’s 2007 Omnibus Equity Incentive Plan as set forth below. 
 (a) Nabi will grant an award of 20,000 shares
of Restricted Stock, which award will vest fully on the Payment Date, and partially if you die or Nabi terminates your employment under Section 7(B) of this Agreement on account of a disability. If the award vests because of the termination of
your employment on account of your death or disability, the number of shares of Restricted Stock that vest will be prorated based upon the number of days elapsed in the Employment Period. For example, if you die 120 days after the Effective Date,
and assuming for purposes of this illustration there are 180 days in the Employment Period, two-thirds (2/3) of the shares of Restricted Stock will vest. 
 (b) Nabi will grant an award of 48,000 shares of Restricted Stock, which award will vest upon the terms and conditions set forth in the attached Exhibit A (the “Performance Award”). 
 (B) The agreements evidencing the Restricted Stock awards (each a “Restricted Stock Agreement”) shall be in substantially the form of the restricted stock
agreements entered into by you and Nabi in connection with your previous Employment Agreement between you and Nabi dated February 15, 2007 (the “Previous Agreement”) filed most recently with the SEC and otherwise consistent with the
terms of this Agreement. 
 5. BENEFITS:  
 (A)
During the Employment Period, you will be eligible to participate in such fringe benefits programs as are accorded generally to other Nabi executive officers and in which you participated on the Effective Date. 
 (B) You hereby elect to participate, to the extent permissible, in the premium payment option under Nabi’s cafeteria plan (as defined under section 125 of Internal
Revenue Code of 1986, as amended (the “Code”)). Provided that your election to participate in such 

  

 2 

 
plan remains in effect, Nabi will pay monthly for each month beginning during the Employment Period up to $1,557 in healthcare insurance premiums on your
behalf under the Pfizer Inc. retiree health plan, with the intent that such payments would be made on a pre-tax basis. If your participation in Nabi’s cafeteria plan on the terms set forth in the immediately preceding sentence is not
permissible, Nabi will instead make a monthly payment to Pfizer, Inc. on your behalf, during each month beginning during the Employment Period, in the amount of $1,557 (or such other reasonable amount as the Pfizer Retiree Plan requires to provide
equivalent benefits), which payment shall be grossed-up for any applicable federal, state and local income taxes, as well as social security and medicare taxes, and for any additional taxes on account of the gross up, to the extent that such payment
is compensation income to you. 
 (C) Nabi will pay you monthly in arrears a per diem fee of $180 to cover food, laundry, gas and other miscellaneous
expenses while you are working at Nabi’s facilities in Rockville, Maryland during the Employment Period. Your travel to other Nabi facilities, including Boca Raton, Florida, will be a reimbursable business expense. The per diem fees will not be
grossed-up for any applicable federal, state or local income taxes, or any social security or medicare taxes. 
 (D) Nabi will (i) provide to you with
an appropriate corporate apartment and rental car for your use and (ii) reimburse you monthly in arrears upon written request for hotel or other lodging, airfares and car rental expenses (other than gas expenses covered by the per diem in
Section 8C of this Agreement) reasonably incurred by you while you are working at the Nabi’s facilities in Rockville, Maryland during the Employment Period. Such reimbursement will be grossed-up for any applicable federal, state and local
income taxes and social security and medicare taxes, and for any additional taxes on account of the gross up, in each case to the extent that such reimbursement would be taxable to you. 
 (E) You will be allowed to take three (3) weeks of paid vacation during the Employment Period under this Agreement and may carry forward any unused vacation time from the agreed entitlement of three
(3) weeks of paid vacation in the Previous Agreement. The value of all vacation time that remains unused at the Expiration Date shall be paid to you in accordance with Nabi’s Paid Leave Bank policy. 
 (F) Nabi will pay legal fees and disbursements reasonably incurred by you in connection with the negotiation of all employment-related agreements, including this
Agreement and the Restricted Stock Agreements. Nabi will pay such legal fees and disbursements directly to your counsel promptly after Nabi’s receipt of an invoice that you have approved from such counsel. 
 (G) Reimbursement of expenses under Sections 5(C) and 5(D) of this Agreement (but not the per diem payment) shall be subject to periodic review by Nabi’s Audit
Committee. You agree to use reasonable efforts to maintain adequate records of all reimbursable expenses necessary to satisfy any reporting requirements of the Code, and applicable Treasury regulations. 
  

 3 

 6. DUTIES AND EXTENT OF SERVICES: 
 (A) During the Employment Period, you agree to devote substantially all of your working time, and such energy, knowledge, and efforts as is necessary, to the discharge and performance of your duties as provided in
this Agreement. You shall be located primarily in Nabi’s Rockville, Maryland facilities, but shall travel to other locations from time to time as shall be reasonably required in the course of performance of your duties. 
 (B) During the Employment Period, you shall serve as interim President and Chief Executive Officer. Subject to the direction and supervision of Nabi’s Board of
Directors and any committee thereof, you shall have full discretionary authority during the Employment Period to control Nabi’s day-to-day operations and to incur such obligations on behalf of Nabi as may be required in the ordinary course of
business. You shall also have such other duties as Nabi’s Board of Directors or any committee thereof may reasonably delegate to you, provided that such duties shall be reasonably consistent with those duties assigned to chief executive
officers in organizations comparable to Nabi. 
 (C) You represent and agree that your employment by Nabi and your performance of all the terms of this
Agreement will not conflict with or violate any agreement that you may have with any other party; and that you will not disclose to Nabi or induce Nabi to use any confidential or proprietary information or material belonging to any previous employer
or other party. 
 7. TERMINATION: 
 (A) The
Employment Period shall terminate upon your death. You may also terminate the Employment Period upon thirty (30) days’ prior written notice to Nabi. 
 (B) Nabi may terminate the Employment Period (a) in the event Nabi reasonably determines that you are unable to perform the essential functions of your position, with or without reasonable accommodation, for any four
(4) consecutive weeks as the result of mental or physical incapacity or (b) for “Cause”, which is defined as (i) any act of fraud or embezzlement or any other felonious act by you that either (a) involves Nabi or
(b) in the case of any such act not involving Nabi, is the subject of an indictment or conviction of you or a nolo contendere plea by you and the Nabi Board of Directors determines in good faith that such indictment, conviction or plea
could reasonably be expected to have a material adverse effect on your business reputation or have a material adverse effect on Nabi, (ii) your refusal to comply with reasonable directions in connection with the performance of your duties as
provided for in Section 6 of this Agreement after written notice of such failure is delivered to you, (iii) failure to comply in any material respect with the provisions of Section 9 of this Agreement or (iv) your gross
negligence in connection with the performance of your duties as provided for in this Agreement with regard to a material matter, provided that, in the event of a proposed termination under clause (ii) or clause (iv) of this clause (B), you
shall receive ten (10) days’ prior written notice of such proposed termination and within such period you shall be afforded an opportunity to be heard by Nabi’s Board of Directors or a duly appointed committee of the Board as to
whether grounds for termination under these clauses exists. 
  

 4 

 (C) Nabi may otherwise terminate the Employment Period upon thirty (30) days’ prior notice to you. 

(D) Your confidentiality agreement set forth in Section 9 below and your agreement to cooperate set forth in Section 10 below shall survive the termination
of your employment regardless of the reasons therefor. 
 8. SEVERANCE; 409A: 
 (A) In the event that your employment terminates for any reason, including a termination without Cause pursuant to Section 7C of this Agreement, you will not be
entitled to receive any severance or other payment on account of such termination except as expressly provided in Section 8B of this Agreement. 
 (B)
If Nabi terminates your employment without Cause prior to the Expiration Date or, a new Chief Executive Officer commences employment with Nabi in such position prior to the Expiration Date (provided that your employment has not been terminated for
Cause), Nabi will make a lump sum payment to you, which payment shall be made on or as soon as practicable after the later of the effective date of your termination (but in no event later than March 15, 2008) in an amount equal to the salary
that you would have received if Nabi had continued to employ you through the Expiration Date. In addition, Section 5(B) shall continue to apply through the Expiration Date. In addition, as provided above, you will receive the full Incentive
Bonus and the Restricted Stock shall fully vest. 
 (C) You and Nabi intend that the provisions of this Agreement and all amounts payable to you under this
Agreement meet the requirements of Section 409A of the Code to the extent applicable, and this Agreement shall be interpreted in accordance with such intent. The parties agree that all payments hereunder to you are either “short term
deferrals” under Section 409A or otherwise exempt from being treated as deferred compensation under Section 409A and will be treated accordingly. A termination of employment shall not be deemed to occur hereunder unless it is a
separation from service as an employee within the meaning of Section 409A. 
 9. CONFIDENTIALITY:  
 (A) You acknowledge that your duties with Nabi will give you access to trade secrets and other confidential information of Nabi and/or its affiliates and of third
parties, including but not limited to information concerning composition, production and marketing of their respective products, customer lists, and other information relating to their present or future operations (all of the foregoing, whether or
not it qualifies as a “trade secret” under applicable law, is collectively called “Confidential Information”). You recognize that Confidential Information is proprietary to each such entity and gives each of them significant
competitive advantage. 
  

 5 

 (B) You agree not to use or disclose any of the Confidential Information during or after the Employment Period, except
for the sole and exclusive benefit of the relevant company and except as may be required by law. Upon Nabi’s request, you will return to the relevant company’s office after the termination of the Employment Period all documents, computer
electronic information and files, e.g., diskettes, floppies etc. and other tangible embodiments of any Confidential Information. 
 (C) You agree that Nabi
would be irreparably injured by any breach of your confidentiality agreement in this Section 9, that such injury would not be adequately compensable by monetary damages, and that, accordingly, the offended company may specifically enforce the
provisions of this Section by injunction or similar remedy by any court of competent jurisdiction without affecting any claim for damages. 
 (D) If you are
legally compelled or otherwise required by a court or regulatory body to disclose any Confidential Information, you will provide Nabi and, if applicable, any other relevant company with prompt written notice of such request, so that the relevant
company may seek, at its sole cost and expense, an appropriate protective order or other appropriate remedy. You agree to use commercially reasonable efforts, at the sole cost and expense of the relevant company, to cooperate with such company in
its efforts to obtain such protective order or other remedy. In the event that such protective order or other remedy is not obtained, you may furnish that portion (and only that portion) of the Confidential Information that, upon the advice of your
counsel, you are legally compelled or otherwise required to disclose. 
 10. LITIGATION AND REGULATORY COOPERATION: During and after your
employment with Nabi, you shall reasonably cooperate with Nabi in the defense or prosecution of any claim now in existence or which may be brought in the future against or on behalf of Nabi which relates to any event or occurrence that transpired
while you were employed by Nabi; provided, however, that such cooperation shall not materially and adversely affect you or expose you to an increased probability of civil or criminal litigation. Your cooperation in connection with such claims or
actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of Nabi at mutually convenient times. During and after your employment with Nabi, you also shall
cooperate fully with Nabi in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by Nabi. Nabi
shall reimburse you for all out-of-pocket costs and expenses incurred in connection with your performance under this Section 10, including, but not limited to, reasonable attorneys’ fees and costs. 
 11. INDEMNIFICATION: Reference is made to that certain Indemnification Agreement dated September 6, 2005 between you and Nabi (the
“Indemnification Agreement”) under which Nabi agreed, among other things, to indemnify you and hold you harmless with respect to any action taken or omitted by you in your capacity as a Nabi director, to the fullest extent permissible
under applicable law, as such law may be amended or supplemented from time to time. You and Nabi hereby agree that the Indemnification 

  

 6 

 
Agreement shall apply equally to any action taken or omitted by you in your capacity as an officer, employee or agent of Nabi or as a director, officer,
employee, member, manager, trustee (or other fiduciary) or agent of any other corporation, limited liability company, partnership, joint venture, trust or other entity or enterprise, whether or not for profit, or any employee benefit plan (or
related trust) sponsored or maintained by Nabi or any subsidiary, as to which you are or were serving in one or more such capacities at the request of Nabi or any of its subsidiaries. You and Nabi further agree that this sentence is intended to be
and shall be construed as an amendment of the Indemnification Agreement within the meaning of Section 18 of the Indemnification Agreement. 
 12.
MISCELLANEOUS: 
 (A) This Agreement and the rights and obligations of the parties pursuant to it and any other instrument or document issued
pursuant to it shall be construed, interpreted and enforced in accordance with the laws of the State of Florida, exclusive of its choice-of-law principles. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and
their respective successors and assigns. 
 (B) The provisions of this Agreement shall be severable and the illegality, unenforceability or invalidity of any
provision of this Agreement shall not affect or impair the remaining provisions hereof, and each provision of this Agreement shall be construed to be valid and enforceable to the full extent permitted by law. 
 (C) In any suit, action or proceeding arising out of or in connection with this Agreement, Nabi shall bear all of its attorneys’ fees and disbursements, including
fees and disbursements on appeal, and if you prevail in such suit, action or proceeding, Nabi shall promptly reimburse you for attorneys’ fees and disbursements reasonably incurred by you in such suit, action or proceeding, including fees and
disbursements on appeal. 
 (D) This Agreement and the Restricted Stock Agreements, each dated the Effective Date, the Employee Invention Agreement dated
February 15, 2007 and the Indemnification Agreement are a complete expression of all agreements of the parties relating to the subject matter hereof, and all prior or contemporaneous oral or written understandings or agreements shall be null
and void. 
 (E) This Agreement cannot be amended or waived orally, or by any course of conduct or dealing, but only by a written agreement signed by the
party to be charged therewith. No delay or omission by either party in exercising any right under this Agreement will operate as a waiver of that or any other right. A waiver or consent given by either party on any one occasion is effective only in
that instance and will not be construed as a bar to or waiver of any right on any other occasion. 
 (F) All notices required and allowed hereunder shall be
in writing, and shall be deemed given upon deposit in the Certified Mail, Return Receipt Requested, first-class postage and registration fees prepaid, and correctly addressed to the party for whom intended at its address set forth under its name
below, or to such other address as has been most recently specified by a party by one or more counterparts, each of which shall constitute one and the same agreement. 
  

 7 

 (G) All references to genders or number in this Agreement shall be deemed interchangeably to have a masculine, feminine,
neuter, singular or plural meaning, as the sense of the context required. 
  

 8 

 If the foregoing confirms your understanding of our agreements, please so indicate by signing in the space provided and
returning a signed copy to us. 
  

			
	 NABI BIOPHARMACEUTICALS
 5800 Park of Commerce Boulevard, N.W.
 Boca Raton, Florida 33487

		
	By:	 	 /s/ Geoffrey F. Cox

		 	Geoffrey F. Cox, Ph.D
		 	Chairman

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Leslie Hudson

	Leslie Hudson, Ph.D
	1028 Princeton Kingston Road
	Princeton, NJ 08540

  

 9Transition/Termination Agreement between Nabi and Fresenius Biotech GmbH

 Exhibit 10.26 
 TRANSITION/TERMINATION AGREEMENT 
 BY AND BETWEEN 
 FRESENIUS BIOTECH GmbH 
 AND 

 NABI BIOPHARMACEUTICALS 
 October 19, 2007 

 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	Page
	 1. DEFINITIONS/INTERPRETATION
	  	1
				
		  	1.1	  	Definitions	  	1
				
		  	1.2	  	Interpretation	  	3
		
	 2. RECONCILIATION OF RIGHTS
	  	4
				
		  	2.1	  	The March 30 Agreement	  	4
				
		  	2.2	  	Certain Rights to Improvements and Trademarks	  	5
				
		  	2.3	  	Packaging and Labeling Requirements	  	5
		
	 3. TRANSITION OBLIGATIONS
	  	5
				
		  	3.1	  	Mutual Obligations	  	5
				
		  	3.2	  	NABI’s Obligations	  	8
				
		  	3.3	  	Obligations of FRESENIUS	  	8
				
		  	3.4	  	Competition Limitations	  	9
		
	 4. COVENANTS, REPRESENTATIONS AND WARRANTIES
	  	9
				
		  	4.1	  	By NABI	  	9
				
		  	4.2	  	By FRESENIUS	  	10
		
	 5. FINANCIAL TERMS
	  	10
				
		  	5.1	  	Currency of Payments	  	10
				
		  	5.2	  	Payments to be made by NABI on the Effective Date	  	10
				
		  	5.3	  	Payments to be made by FRESENIUS after the Effective Date	  	11
				
		  	5.4	  	Disbursement of the Residual Escrow Amount	  	13
				
		  	5.5	  	Interest on Escrow Funds	  	13
				
		  	5.6	  	Settlement and Release	  	13
		
	 6. CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS
	  	14
				
		  	6.1	  	Confidentiality	  	14
				
		  	6.2	  	Confidential Treatment	  	15
				
		  	6.3	  	Exclusions	  	15
				
		  	6.4	  	Public Announcements	  	16

  

 - i - 

							
	 7. INDEMNIFICATION AND INSURANCE
	  	16
				
		  	 7.1
	  	Indemnification by FRESENIUS	  	16
				
		  	 7.2
	  	Indemnification by NABI	  	17
				
		  	 7.3
	  	Third Party Claims	  	17
				
		  	 7.4
	  	Procedure for Other Claims	  	18
				
		  	 7.5
	  	Product Liability Insurance	  	19
				
		  	 7.6
	  	Special, Indirect or Like Damages	  	19
				
		  	 7.7
	  	Specific Performance	  	19
		
	 8. MISCELLANEOUS
	  	20
				
		  	 8.1
	  	Jurisdiction and Dispute Resolution	  	20
				
		  	 8.2
	  	Force Majeure	  	20
				
		  	 8.3
	  	Relationship of the Parties	  	21
				
		  	 8.4
	  	Assignment	  	21
				
		  	 8.5
	  	Binding Effect	  	22
				
		  	 8.6
	  	Entire Agreement	  	22
				
		  	 8.7
	  	Compliance with Laws	  	22
				
		  	 8.8
	  	Notices	  	23
				
		  	 8.9
	  	Severability	  	23
				
		  	 8.10
	  	Waiver of Modification of Agreement	  	24
				
		  	 8.11
	  	Headings	  	24
				
		  	 8.12
	  	Counterparts	  	24
				
		  	 8.13
	  	Further Assurances	  	24

  

 - ii - 

 TRANSITION/TERMINATION AGREEMENT 
 BY AND BETWEEN 
 FRESENIUS BIOTECH GmbH 
 AND 
 NABI BIOPHARMACEUTICALS 

 This TRANSITION/TERMINATION AGREEMENT (the “Agreement”) dated the 19th day of October 2007 with
respect to the AGREEMENT TO DEVELOP, SUPPLY AND MARKET ATG – FRESENIUS NORTH AMERICA dated as of the 30th day of March, 2006 (the “March 30 Agreement”), is entered into by and between FRESENIUS BIOTECH GmbH, a
company organized under the laws of the Federal Republic of Germany having a principal place of business at Am Haag 6-7, 82166 Graefelfing, Germany, hereinafter referred to as “FRESENIUS” and NABI BIOPHARMACEUTICALS, a
corporation organized under the laws of Delaware having a principal place of business at 5800 Park of Commerce Blvd. N.W., Boca Raton, Florida 33487 USA, hereinafter referred to as “NABI”. 
 RECITALS 
 WHEREAS, it is agreed by the parties that it is in their mutual best interest to enter into in this Agreement, 
 NOW THEREFORE, in consideration of the mutual covenants set forth below, the parties agree as follows: 
 AGREEMENT

  

	 	1.	DEFINITIONS/INTERPRETATION 

  

	 	1.1	Definitions 

 In addition to definitions
set forth throughout this Agreement, the following capitalized terms shall have the meanings ascribed to them below: 
 A.
“Affiliate(s)” means, with respect to any specified Person, any other Person that, directly or indirectly, through one or more intermediaries, is in Control of, is Controlled by, or is under common Control with, such specified
Person. For purposes of this definition, “control” (including with its correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any Person, shall mean the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or by contract or otherwise. 
 B. “Assigned Contracts” means the agreements identified in Section 3.2D(i), (ii) and (iii). 
  

 1 

 C. “ATG” and “ATG Global” means an immunosuppressive polyclonal
antibody sometimes referred to as EZ 2053. 
 D. “Business Day” means each day which is a normal day of business in Bad
Homburg, Germany and Boca Raton, Florida or the next business day if such day falls on a legal holiday in either such city. 
 E.
“Competitive Product” means a polyclonal antibody other than the Licensed Product which is sold commercially: (a) in the case of solid organ transplants: (i) for induction therapy (prophylaxis of organ rejection), or
(ii) to treat transplant rejection, excluding in either case immunosuppressant drugs which are used in maintenance therapy; and (b) in the case of stem cell transplants, to prevent and treat graft versus host diseases. For purposes of this
definition: (x) a polyclonal antibody which is approved for and marketed generally as a substitute for, or which is openly marketed as a product which can be used as a substitute for, the Licensed Product shall be a Competitive Product; and
(y) a polyclonal antibody (other than a product described in the preceding clause) which is used only in co-therapy (and is not otherwise approved or marketed as a substitute for the Licensed Product) shall not be deemed to be a Competitive
Product. 
 F. “Confidential Information” means any information of either party or of any of their Affiliates which is not
generally known, the continued secrecy of which information provides the possessor of this information with some economic advantage, and which the possessor of this information has taken reasonable steps under the circumstances to keep secret.

 G. “Data” is defined in Section 3.2A. 
 H. “Damages” is defined in Section 7.1. 
 I. “Effective Date” means
the date of this Agreement. 
 J. “End Date” means midnight on October 19, 2007. 
 K. “FRESENIUS ATG Trademarks” means the Trademark “Fresenius.” 
 L. “GCP” means the current good clinical practices regulations of the US FDA. 
 M. “Improvements” means any modification or change to ATG, whether or not any such modification or change is patentable, including:
(i) any composition which includes ATG; (ii) any substitute for ATG that is based on or utilizes ATG; and (iii) any process for making or using ATG, or any composition which includes, or is a substitute for, ATG as described above.

 N. “IND” means an Investigational New Drug application filed with the US FDA. 
 O. “Intellectual Property Rights” means a party’s (i) patents and patent applications that claim a composition including, or a
method of using, Licensed Product; (ii) Know-How and trade secrets concerning the manufacture, processing, marketing, distribution, or pricing of Licensed Product; (iii) FRESENIUS ATG Trademarks used in conjunction with Licensed Product;
(iv) copyrights in works used in conjunction with the manufacturing, processing, marketing, distribution or pricing of Licensed Product; (v) rights to 

  

 2 

 
use and rely upon any clinical data concerning Licensed Product; and (vi) the right to reference any filing with a governmental regulatory authority for
approval to market Licensed Product. 
 P. “Know-How” means all know-how relating to the Licensed Product including clinical
data, manufacturing data, and test and measurement data, but only to the extent that such know-how and any data included therein is used or useful in, or necessary for, marketing of ATG or is necessary for a party to comply with its obligations
under this Agreement. 
 Q. “Licensed Product” means ATG and all Improvements thereto that are either owned or controlled by
FRESENIUS at any time during the term of this Agreement. 
 R. “NABI Trademarks” means the registered trademarks of NABI
used in connection with the marketing, promotion, distribution and sale of Licensed Products in the Territory. 
 S. “NABI’s
Scheduled Obligations” means NABI’s obligations set forth on Schedule 4 of this Agreement. 
 T. “Out-of-Pocket
Costs” means all reasonable expenses paid or payable by NABI to third parties. 
 U. “Person” means any individual,
corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, estate, unincorporated organization, governmental, judicial or regulatory body, business unit, division or other entity. 

V. “Released Claims” means all claims, debts, suits, actions, cause of actions, controversies, demands, rights, damages, losses,
expenses, costs, attorneys’ fees, compensation, liabilities, obligations and claims of every kind and nature whatsoever arising out of, based on, or attributable to, the March 30 Agreement, the Licensed Product and the transactions, acts
and omissions of the parties with respect thereto. 
 W. “Study” means each study and program undertaken (or planned to be
undertaken) by NABI for the clinical development of ATG. 
 X. “Territory” means Canada and the United States. 

Y. “US FDA” means the US Food and Drug Administration as defined above, or any successor agency. 
  

	 	1.2	Interpretation 

 The parties have
participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption of burden of
proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. References in this Agreement to any gender include references to all genders, and references to the singular include
references to the plural and vice versa. The words “include”, “includes” and “including” when used in this Agreement 

  

 3 

 
shall be deemed to be followed by the phrase “without limitation”. Unless the context otherwise requires, references in this Agreement to Articles,
Sections, Exhibits, Schedules, Appendices and Attachments shall be deemed references to Articles and Sections of, and Exhibits, Schedules, Appendices and Attachments to, this Agreement. Unless the context otherwise requires, the words
“hereof,’” “hereby” and “herein” and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Article, Section or provision of this Agreement.

  

	 	2.	RECONCILIATION OF RIGHTS 

  

	 	2.1	The March 30 Agreement 

 Subject only
to payment in full by NABI of the amounts specified in Section 5.2A as therein provided, the March 30 Agreement is terminated as of the Effective Date (including without limitation those provisions thereof which purport to govern after the
termination or expiration of such agreement) except that: 
 (i) Section 2.1 thereof is incorporated herein and shall
continue through the End Date and thereafter as may be reasonably necessary for the parties to perform the services, and take the actions necessary, for the transition of the Studies including delivery of the Data and assignment of the Assigned
Contracts from NABI to FRESENIUS (or its designees), as set forth in this Agreement; 
 (ii) In order to plan for an orderly
transition and avoid injury that may result if the obligations of NABI were abruptly terminated, NABI shall continue its efforts in prosecuting the lung Study between the Effective Date and the End Date consistent with its efforts expended on the
lung Study during 2007 prior to the Effective Date and shall be responsible for and shall bear (and FRESENIUS shall not incur any responsibility or liability for) any and all costs, including but not limited to investigator fees, laboratory costs,
and monitoring costs, which are attributable to NABI’s conduct and continuation of the lung Study through the End Date even if the steps establishing NABI’s liability for such costs are partially completed after the End Date (for example,
collection of samples or completion of reports after the End Date for patient visits or treatments occurring before the End Date, or completion of interim data analysis in respect thereof) (collectively, “NABI’s Pre-End Date Accrued
Liabilities”); and 
 (iii) Sections 4.1(E), 4.1(F), 4.4, 5.1 (but only in respect of the lung Study), 5.7, 5.8,
5.9, 5.10, 6.1, 7.6, 7.7 and 8, of the March 30 Agreement are incorporated herein and shall continue through the End Date (and to the extent necessary to discharge the obligations of NABI in accordance with the terms of this Agreement after the
End Date) whereupon they shall terminate. 
  

 4 

	 	2.2	Certain Rights to Improvements and Trademarks 

 A. NABI
hereby grants to FRESENIUS an exclusive, worldwide, royalty-free, milestone-free, perpetual license, with the right to sublicense, to make, use, sell, offer for sale each of the Improvements that is or was either owned, or controlled with the right
to sublicense, by NABI at any time during the term of the March 30 Agreement, if any. 
 B. After the Effective Date FRESENIUS shall not
use any NABI Trademarks except to the extent necessary in connection with the transition of the Studies (and then only insofar as reference to NABI is necessary) or to the extent the NABI Trademarks are included on a product as to which
Section 2.3 shall apply. 
  

	 	2.3	Packaging and Labeling Requirements. 

 As
of the End Date all of the Licensed Product in the possession of third parties by reason of agreements between NABI and each such third party shall be the property of the third party to the extent mandated by the relevant agreement with such third
party or if not so mandated shall be the property of FRESENIUS. If such Licensed Product is labeled with the NABI Trademarks, FRESENIUS is hereby granted a limited, worldwide, royalty-free license to use the same until such Licensed Product is
exhausted or is otherwise properly disposed of in accordance with business practices applicable in the industry. NABI represents and warrants that, except for Licensed Product held for NABI’s account at the third party drug depositary
referenced in Section 3.2E, NABI does not have any Licensed Product in its possession or control. 
  

	 	3.	TRANSITION OBLIGATIONS 

  

	 	3.1	Mutual Obligations 

 Immediately on the
Effective Date, the parties shall each use their best efforts to complete such regulatory steps and to execute and deliver such assignments, transmittal letters, minutes and documentation as are required to transfer the INDs (and non-U.S.
equivalents in Canada, Austria and Australia) and the sponsorship, ownership and operation of, and liability to third parties consistent with this Agreement for, the Studies from NABI to FRESENIUS (or its designees) in the United States, Canada,
Austria and Australia on or as soon after the End Date as is practical, but in no event in any such jurisdiction later than December 6, 2007 (the earlier of December 6, 2007 and the date such transfer is completed in each jurisdiction
being herein called the “Transfer Effectiveness Date”). 
  

	 	3.2	NABI’s Obligations 

 A. Without limiting
Section 3.1, NABI shall, at its cost and expense, fully and promptly cooperate with FRESENIUS through the End Date in connection with the transition from NABI to FRESENIUS (or its designees) of responsibility for the current lung Study, renal
Study and stem cell transplant Study, and not later than October 25, 2007, NABI shall (i) fulfill all of NABI’s Scheduled Obligations and (ii) deliver to FRESENIUS (or its designees), such of the following as are in its
possession or under its control with respect to ATG or NABI’s activities undertaken pursuant to the March 30 Agreement: all data, studies, analyses, technological, 

  

 5 

 
commercial, business-related and other information including but not limited to all assignable contracts, any and all submissions and responses received from
any governmental authority, complete documentation and information on the lung Study, the renal Study and stem cell transplant Study, preclinical data, status application of a CAS number (if any), all information on orphan drug designation status,
investigators’ brochures, status of the distribution of clinical vials and study drug, as well as all consents and waivers necessary to have access to the source data documentation, all correspondence with the FDA together with submissions and
approvals (and their counterparts in Canada, Australia and Austria) for the Licensed Product as well as all emails and electronic copies of the foregoing, and any marketing approval studies, analysis and/or documents necessary for the IND or
marketing approval (the “Data”); provided, however, NABI shall be permitted to retain copies of such of the Data and deliveries required by NABI’s Scheduled Obligations as are necessary to fulfill its obligations under
Section 3.2B. If NABI receives any Data or other documentation contemplated by the foregoing sentence after October 25, 2007, NABI, at its cost and expense, shall deliver to FRESENIUS (or its designees) such Data and documentation by the
Transfer Effectiveness Date. 
 B. In addition to its obligations set forth in Sections 3.1 and 3.2A above, after the End Date NABI will
provide the following consulting services to FRESENIUS: 
 (i) Until December 6, 2007 NABI shall, at its cost and
expense, fully and promptly cooperate with FRESENIUS’ reasonable written requests to complete the physical or electronic transfer to FRESENIUS (or its designee) of the current lung Study data base, trial master file and safety data base;

 (ii) NABI shall, at FRESENIUS’ cost and expense in accordance with Section 5.3A(ii), between the End Date and
December 6, 2007, fully and promptly cooperate with FRESENIUS’ reasonable written requests to provide consulting assistance to complete the transition of other aspects (excluding those described in Section 3.2B(i)) of the current lung
Study to FRESENIUS (or its designees); and 
 (iii) In each jurisdiction where the Transfer Effectiveness Date has not
occurred by the End Date, the consulting services to be provided by NABI at the cost and expense of FRESENIUS (in accordance with Section 5.3 A (ii)) shall include NABI’s continuation as the sponsor of the lung Study until the Transfer
Effectiveness Date in such jurisdiction; provided, however, that in such event FRESENIUS shall cooperate fully with such efforts at its sole cost and expense and FRESENIUS shall be responsible for and shall bear (and NABI shall not incur any
responsibility or liability for) any and all of NABI’s Out of Pocket Costs incurred in connection with such efforts, including but not limited to investigator fees, laboratory costs, and monitoring costs, even if the steps establishing the
liability for such costs are partially completed after the Transfer Effectiveness Date (for example, collection of samples or completion of reports after the Transfer Effectiveness Date for patient visits or treatments occurring between the End Date
and the Transfer Effectiveness Date, or completion of interim data analysis in respect thereof); 
  

 6 

 provided, however, that in all of the above cases, NABI shall have no right to charge FRESENIUS for or in respect of
NABI’S Pre-End Date Accrued Liabilities or for the fulfillment of other obligations which are specifically at the cost and expense of NABI pursuant to the express terms of this Agreement. 
 C. To the extent that any Data maintained by NABI (or its service providers) requires special software which is sub-licensable by NABI and not
commercially available in shrink wrapped packages and commonly available at a cost less than $1,000, or to the extent that NABI has developed any proprietary software application interface or other software which was specifically developed for Data
utilized in connection with the development of Licensed Product under the March 30 Agreement, NABI hereby grants to FRESENIUS (or its designees) a non-exclusive, royalty free, perpetual, worldwide license to use such software and software
application interface for the sole purpose of accessing and transferring the Data and NABI shall provide such software to FRESENIUS (or its designees) in a machine readable format together with the source code if such source code is available to
NABI. 
 D. On the Transfer Effectiveness Date in each jurisdiction, NABI shall at its cost and expense assign and, if in NABI’s
possession or under its control, deliver to FRESENIUS (or its designees): 
 (i) the agreements in effect with respect to
such jurisdiction that may be assigned without consent as set forth on Schedule 1 to this Agreement; 
 (ii) the
unexecuted, pending agreements in effect in such jurisdiction set forth on Schedule 2 to this Agreement (to the extent NABI has any rights therein) (the “Pending Agreements”); and 
 (iii) the agreements in effect in such jurisdiction that may be assigned only with the consent of the counterparty thereto as set forth
on Schedule 3 to this Agreement. 
 E. At such time as is specified by FRESENIUS not later than the Transfer Effectiveness Date in each
applicable jurisdiction, NABI shall deliver to FRESENIUS’ account at the third party drug depositary where the Licensed Product is stored by NABI, without charge, all quantities of Licensed Product which are in the possession or control of
NABI, provided that FRESENIUS shall take into consideration in making such request for delivery, the reasonable requirements of NABI to fulfill its responsibilities with respect to the delivery of Licensed Product to clinical sites on or prior to
the Transfer Effectiveness Date in each applicable jurisdiction. 
 F. Upon reasonable advance written notice given by FRESENIUS to NABI,
FRESENIUS shall have the right to conduct, prior to the End Date and at its sole cost and expense, one GCP audit (including without limitation system/organization, documentation, data management, pharmacovigilance, on-site visits, service providers,
trial master file (“TMF”)) at the facilities of NABI with respect to the lung Study. 
  

 7 

 G. Except as may be necessary in connection with the transition of the Studies and the completion of
NABI’s obligations under this Agreement, the Quality Agreement and the Safety Data Exchange Agreement shall be terminated as of the Transfer Effectiveness Date in each applicable jurisdiction, provided, however, NABI shall promptly report to
FRESENIUS any information which is received by NABI from Study centers and investigators, and governmental authorities after the Transfer Effectiveness Date in each applicable jurisdiction with respect to the lung Study or the health and safety of
patients which would have been required to have been reported by NABI to FRESENIUS under the Safety Data Exchange Agreement had such agreement not been terminated. 
 H. Subject to NABI’s having complied with its obligations under Sections 3.2A and 3.2B with respect to the transfer to FRESENIUS (or its designees) of the lung Study data base, trial master file and safety data
base, NABI shall have no obligation to take any actions, incur any expenses, perform any services or assist FRESENIUS in any way in respect of continuation of the current lung Study, the transition of the Studies to FRESENIUS or the development of
ATG within or without the Territory after December 6, 2007 except to the limited extent set forth in the proviso to Section 3.2G above. 
 I. In the event that the transactions contemplated by this Agreement involve the assignment of rights under any contract, agreement, license or claim, or of other rights, assets, or property, which are nonassignable without the consent,
authorization or approval of the other party or parties thereto or any other third party or governmental entity (a “Nonassignable Contract”), and such consent, authorization or approval shall not have been obtained by NABI prior to
the Transfer Effectiveness Date applicable to such contract despite commercially reasonable efforts by NABI, then, notwithstanding anything in this Agreement to the contrary (and without relieving NABI of any liability or obligation it may have
under this Agreement), any such Nonassignable Contract shall not be assigned (except any rights to receive payments thereunder) until all such necessary consents, authorizations and approvals with respect to such Nonassignable Contract shall have
been obtained, whereupon NABI shall, without further consideration, promptly assign or cause the assignment of same to FRESENIUS. Notwithstanding any other provision in this Agreement, in the event that NABI complies with this Section 3.2I,
NABI shall not be held liable or accountable for failing to deliver, assign or make available to FRESENIUS any of the Nonassignable Contracts. 
 J. For the purposes of the deliveries to be made by NABI to FRESENIUS pursuant to this Agreement, delivery by NABI (i) electronically to FRESENIUS or (ii) in the case of physical delivery, to the carrier or delivery service
specified by FRESENIUS, addressed as specified by FRESENIUS, will constitute satisfactory delivery by NABI. 
  

	 	3.3	Obligations of FRESENIUS 

 A. As of the Transfer
Effectiveness Date in each jurisdiction FRESENIUS shall assume and perform the obligations under the Assigned Contracts in effect with respect to such jurisdiction exclusive of payment obligations that are included among NABI’s Pre-End Date
Accrued Liabilities (which shall remain as the obligations of NABI to be discharged by NABI in accordance with 

  

 8 

 
Section 2.1(ii)). On the date delivered by NABI, FRESENIUS shall accept delivery of the Data and the other deliveries specified in Section 3.2
including without limitation the lung Study data base, trial master file and safety data base. 
 B. No later than the End Date, FRESENIUS or
its designees shall give notice to all relevant organizations, Persons, clinicians, vendors, consultants and others who are involved with the lung Study and the program relating to the ATG, that FRESENIUS is taking control of the Studies and the
program relating to ATG. 
  

	 	3.4	Competition Limitations 

 Neither NABI nor
any of its Affiliates shall, for a period of three (3) years commencing on the End Date, conduct any studies or programs relating to any Competitive Product, or market, sell, manufacture for sale, or distribute in the Territory any Competitive
Product or acquire (by purchase, license or otherwise) rights in the Territory to market, sell or distribute any Competitive Product; provided, however, that this Section 3.4 shall not apply to any Affiliate of NABI who becomes such as a result
of having acquired all or substantially all of NABI’s capital stock or assets or as a result of having had substantially all its capital stock or assets acquired by NABI; provided further, however, that any such Affiliate shall in all events be
bound by the provisions of Section 6.1B. 
  

	 	4.	COVENANTS, REPRESENTATIONS AND WARRANTIES 

  

	 	4.1	By NABI 

 NABI covenants, represents and
warrants to FRESENIUS that: 
 A. NABI is a legal entity duly organized and validly existing under the laws of its state and/or country of
incorporation, as applicable, NABI has full power and authority to enter into this Agreement, and to consummate the transactions contemplated hereby; the execution, delivery and performance by NABI of this Agreement has been duly and validly
authorized and approved by all necessary action on the part of NABI; and except as set forth on Schedule 3 to this Agreement, neither the execution and delivery by NABI nor its performance of this Agreement is subject to obtaining any consents or
approvals of any other Person, will conflict with, result in a breach of, or constitute a default under, any contract to which NABI is a party or by which it or any of its assets may be bound, or will result in the creation of any lien upon any of
the assets of NABI. 
 B. Except for the Pending Agreements, all Assigned Contracts are in full force and effect, NABI has not received any
written notice alleging any default or any other irregularity with respect to the Assigned Contracts and NABI has no reason to believe that the parties to such contracts are in, nor will, default in the performance of their respective obligations
thereunder or that NABI has defaulted in its obligations under such Assigned Contracts. 
 C. NABI has fully performed and discharged or will
fully perform and discharge all of its obligations (including but not limited to payment obligations) under the Assigned Contracts, other than the Pending Agreements, through the End Date (even if such payment obligations are invoiced after the End
Date). NABI shall not take any action between the Effective Date and the End Date to cause any Assigned Contract, exclusive of the Pending Agreements, to fail to be in full force and effect on the End Date. 
  

 9 

 D. NABI has delivered to FRESENIUS true and correct copies of all of the Assigned Contracts in its
possession or under its control, together with all amendments, modifications, waivers and consents relating thereto and the correspondence files pertinent thereto, and except as delivered to FRESENIUS, there are no other amendments, modifications,
waivers or consents relating to such Assigned Contracts. 
 E. NABI is not aware of any claim, lawsuit, arbitration, investigation or
action which has been threatened against NABI, or any Persons with whom NABI has dealt, with respect to the Studies.
 F. Since
March 30, 2006, NABI has not filed any claim, or given any notice regarding a claim, to its insurers with respect to any Study. 
  

	 	4.2	By FRESENIUS 

 FRESENIUS covenants,
represents and warrants to NABI that FRESENIUS is a legal entity duly organized and validly existing under the laws of its state and/or country of incorporation, as applicable; FRESENIUS has full power and authority to enter into this Agreement, and
to consummate the transactions contemplated hereby; the execution, delivery and performance by FRESENIUS of this Agreement has been duly and validly authorized and approved by all necessary action on the part of FRESENIUS; and neither the execution
and delivery by FRESENIUS nor its performance of this Agreement is subject to obtaining any consents or approvals of any other Person, will conflict with, result in a breach of, or constitute a default under, any contract to which FRESENIUS is a
party or by which it or any of its assets may be bound, or will result in the creation of any lien upon any of the assets of FRESENIUS. 
  

	 	5.	FINANCIAL TERMS 

  

	 	5.1	Currency of Payments 

 All payments made
under this Agreement shall be made in US$. 
  

	 	5.2	Payments to be made by NABI on the Effective Date 

 A. On
the Effective Date, NABI shall pay the sum of TWO MILLION FOUR HUNDRED EIGHTY-ONE THOUSAND NINE HUNDRED SEVENTY-NINE DOLLARS ($2,481,979) by wire transfer as follows: (a) $2,231,979 to an account specified by FRESENIUS in writing and
(b) $250,000 to an interest bearing account with US Bank (the “Escrow Agent”) to be governed by the escrow agreement executed simultaneously herewith by the Escrow Agent, NABI and FRESENIUS (the “Escrow
Agreement” and said $250,000 together with interest earned thereon, the “Residual Escrow Amount”). 
 B. The
parties agree that said $2,481,979 (i) is the agreed amount to resolve and settle all Released Claims between the parties and (ii) has been calculated as follows: 
 (i) The sum of Three Million Five Hundred Thousand Dollars ($3,500,000), being the agreed amount payable by NABI in consideration for the
assumption by FRESENIUS of NABI’s obligation under the March 30 Agreement to continue the lung Study during the balance of the calendar year 2007 and the entirety of calendar year 2008; less 
  

 10 

 (ii) The sum of Five Hundred Eighty Three Thousand Twenty One Dollars ($583,021)
credited to NABI and applied against and deducted from the sum set forth in clause (i) above, being the amount claimed by NABI as due and owing by FRESENIUS to NABI by reason of the obligation of FRESENIUS to pay NABI certain amounts in respect
of the transition of the lung Study from Enzon Pharmaceuticals Inc. to NABI under the March 30 Agreement; less 
 (iii)
The sum of Four Hundred Thirty-Five Thousand Dollars ($435,000) credited to NABI and applied against and deducted from the sum set forth in clause (i), being the agreed amount payable to third parties and NABI’s internal costs, whether or not
currently due, with respect to NABI’S continuation of the lung Study through the End Date. 
  

	 	5.3	Payments to be made by FRESENIUS after the Effective Date 

 A. FRESENIUS shall pay the following amounts to NABI: 
 (i) 100% of NABI’s
Out-of-Pocket Costs incurred in respect of Nonassignable Contracts between the End Date and the date such contracts are assigned to FRESENIUS as contemplated by Section 3.2I, except that FRESENIUS shall not be required to pay any of NABI’s
Pre-End Date Accrued Liabilities; and 
 (ii) The sum of (a) 100% of NABI’s Out-of-Pocket Costs incurred in
fulfilling any of its obligations under Sections 3.2B(ii) and 3.2B(iii) of this Agreement, (b) the following amounts in respect of Matt Hohenboken, and Michelle Gillen payable to NABI weekly in advance on each Monday commencing October 22,
2007 and ending with the payment due on December 3, 2007 unless at least two (2) weeks prior to any such Monday FRESENIUS delivers to NABI, with a copy to the Escrow Agent, a written notice that the services of any such individual will no
longer be required: 
  

	 	•	 	 Matt Hohenboken: $9,000 

  

	 	•	 	 Michelle Gillen: $4,500 

 and
(c) for any other NABI personnel providing services to FRESENIUS pursuant to Sections 3.2B(ii) or 3.2B(iii), the rate of $225 per hour for the time expended in performing such services provided, however, that this Section shall not give any
right to NABI to impose any charge for activities or costs that are NABI’s sole responsibility and liability as provided in Sections 2.1(ii), 3.1 and 3.2 of this Agreement. 
  

 11 

 B. Amounts payable to NABI pursuant to this Section 5.3 shall be paid as follows:

 (i) NABI’s claims for payment under this Section 5.3 shall be set forth in a written claim for reimbursement
itemizing the amounts claimed and providing copies of invoices from third parties evidencing all components of NABI’s claim that are Out-of-Pocket Costs. NABI’s claims for payment shall be delivered to the Escrow Agent with a copy to
FRESENIUS. 
 (ii) NABI’s claims for payment pursuant to and complying with Section 5.3A(ii)(b) above may not be
disputed by FRESENIUS and shall be paid by the Escrow Agent promptly after receipt. 
 (iii) NABI’s claims for payment
complying with Section 5.3B(i) above (exclusive of those made under clause (b), which may not be contested), that are not disputed by FRESENIUS in a writing delivered to the Escrow Agent, with a copy to NABI, within 20 days of the date of
NABI’S claim for reimbursement shall be paid to NABI by the Escrow Agent promptly following such 20th day. If FRESENIUS shall dispute any such claim for reimbursement in writing within such 20 days, the Escrow Agent shall not pay such claim
except as thereafter provided in a joint written direction received from NABI and FRESENIUS or a court order. 
 (iv)
Anything in this Section 5.3 to the contrary notwithstanding, NABI may in its sole discretion present to FRESENIUS for payment by it directly, invoices received by NABI from third parties as a result of NABI’s performance of its
obligations under Section 3.2B(iii). FRESENIUS agrees to pay all such invoices promptly following receipt. 
 (v) If the
funds held in escrow under the Escrow Agreement shall be insufficient to pay NABI the full amount it is owed pursuant to this Agreement, such amount(s) shall be paid by FRESENIUS directly. 
 C. 
 (i) If
FRESENIUS shall challenge any claim or group of claims for payment, and a court shall find that the amount of such claim or group of claims is overstated by more than ten percent (10%) of the amount of such claim or group of claims for which
FRESENIUS is liable pursuant to the terms of this Agreement, then NABI shall pay the reasonable out of pocket costs and expenses (including of outside lawyers and accountants) incurred by FRESENIUS in contesting such claim or group of claims.

 (ii) If FRESENIUS shall challenge any claim or group of claims for payment and a court shall find that the amount of such
claim or group of claims is not overstated by more than ten percent (10%) of the amount of such claim or group of claims for which FRESENIUS is liable pursuant to the terms of this Agreement, then 

  

 12 

 
FRESENIUS shall pay the reasonable out of pocket costs and expenses (including of outside lawyers and accountants) incurred by NABI in defending such claim
or group of claims. 
  

	 	5.4	Disbursement of the Residual Escrow Amount 

 The Escrow Agent shall disburse the Residual Escrow Amount (excluding interest earned thereon) to NABI in accordance with Section 5.3 until such amounts that have been claimed by NABI through January 31, 2008 have been paid in
full or determined to be not payable. NABI and FRESENIUS shall prepare and jointly sign a reconciliation of the Residual Escrow Amount and direction to the Escrow Agent as to the disbursement of the balance of the Residual Escrow Amount on or before
February 21, 2008 (the “Reconciliation”). The balance of the Residual Escrow Amount (including interest earned thereon) held by the Escrow Agent shall be paid as directed in the Reconciliation. In the event that the
Reconciliation is not completed and jointly signed for any reason, the balance of the Residual Escrow Amount shall be retained in escrow pending presentation of a joint written direction received from NABI and FRESENIUS or a court order. 

 

	 	5.5	Interest on Escrow Funds. 

 No interest
accruing on the funds held in escrow shall be disbursed by the Escrow Agent to NABI or FRESENIUS, as the case may be, as each payment is made by the Escrow Agent out of the Residual Escrow Amount. Such interest shall be allocated between NABI and
FRESENIUS in the same manner and to the same extent as any payment of principal out of the Residual Escrow Amount and shall be paid by the Escrow Agent as directed in the Reconciliation. In the event that the Reconciliation is not completed and
jointly signed for any reason, the balance of the Residual Escrow Amount shall be retained in escrow pending presentation of a joint written direction received from NABI and FRESENIUS or a court order. 
  

	 	5.6	Settlement and Release 

 A. As of the Effective Date, NABI,
on behalf of itself and each of its past or present, agents, employees, representatives, partners, licensees, attorneys, transferees, predecessors, successors, assigns, owners, shareholders, officers, directors, parents, and Affiliates (the
“NABI Releasors”) does hereby irrevocably release, acquit and forever discharge FRESENIUS and each of its past or present agents, employees, representatives, partners, licensees, attorneys, transferrees, predecessors, successors,
assigns, owners, shareholders, officers, directors, parents, and Affiliates (the “FRESENIUS Releasees”) of or from any and all debts, suits, actions, causes of action, controversies, demands, rights, damages, losses, expenses,
costs, attorneys’ fees, compensation, liabilities, obligations and claims of every kind and nature whatsoever, suspected or unsuspected, known or unknown, foreseen or unforeseen, that the NABI Releasors or any of them may now have or at any
time may have had against the FRESENIUS Releasees with respect to the Released Claims, up to and including the Effective Date, provided, however, that nothing set forth herein shall be deemed to affect, release or waive any rights against, and/or
obligations of, FRESENIUS as provided in this Agreement including, notwithstanding the termination of the March 30 Agreement, in respect of any breach by FRESENIUS of Section 9 of the March 30 Agreement occurring prior to the
Effective Date as contemplated by Section 7.1B. 
  

 13 

 B. Subject only to payment in full by NABI of the amounts specified in Section 5.2A as therein
provided, as of the Effective Date, FRESENIUS, on behalf of itself and each of its past or present, agents, employees, representatives, partners, licensees, attorneys, transferees, predecessors, successors, assigns, owners, shareholders, officers,
directors, parents, subsidiaries and Affiliates (the “FRESENIUS Releasors”) does hereby irrevocably release, acquit and forever discharge NABI and each of its past or present agents, employees, representatives, partners,
licensees, attorneys, transferrees, predecessors, successors, assigns, owners, shareholders, officers, directors, parents, subsidiaries and Affiliates (the “NABI Releasees”) of or from any and all debts, suits, actions, causes of
action, controversies, demands, rights, damages, losses, expenses, costs, attorneys’ fees, compensation, liabilities, obligations and claims of every kind and nature whatsoever, suspected or unsuspected, known or unknown, foreseen or
unforeseen, that the FRESENIUS Releasors or any of them may now have or at any time may have had against the NABI Releasees with respect to the Released Claims, up to and including the Effective Date, provided, however, that nothing set
forth herein shall be deemed to affect, release or waive any rights against, and/or obligations of, NABI as provided in this Agreement including, notwithstanding the termination of the March 30 Agreement, in respect of any breach by NABI of
Section 9 of the March 30 Agreement occurring prior to the Effective Date as contemplated by Section 7.2B. 
 C. For the sake
of clarity, neither NABI nor FRESENIUS releases the other under Sections 5.6B or 5.6C, with respect to the indemnity obligations set forth in Section 7 of this Agreement. 
 D. Notwithstanding anything in this Agreement to the contrary, in the event that NABI fails to make the payments required under Section 5.2A as
therein provided, this Agreement shall become null and void as if it had never been executed and the parties shall be returned to the positions they were in before this Agreement was executed. 
  

	 	6.	CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS 

  

	 	6.1	Confidentiality 

 A. Each party on behalf of itself and its
Affiliates and sublicensees agrees that Confidential Information of the other party may only be used for the purpose of the activities contemplated by this Agreement and may not be disclosed to a third party except in accordance with the provisions
of this Agreement. The parties shall ensure that their Affiliates and sublicensees keep all of the other party’s Confidential Information confidential in accordance with the provisions hereof as though the Affiliates and sublicensees were
parties hereto EXCEPT THAT, FRESENIUS shall have the full right to use all Confidential Information respecting ATG which is delivered by NABI under Section 3.2 and any Improvements. Each party shall be liable for any breach hereof by its
Affiliates and sublicensees. 
 B. The parties expressly agree that it shall be a material breach of NABI’s obligations under this
Agreement for NABI to use, or to provide to any third party (including any present or future Affiliate) for use, any Confidential Information of FRESENIUS, other than as permitted by this Agreement or to develop a Competitive Product. If any
(i) Affiliate of NABI becomes such as a result of 

  

 14 

 
having acquired all or substantially all of NABI’s capital stock or assets, (ii) Person becomes an Affiliate of NABI as a result of having had
substantially all its capital stock or assets acquired by NABI, or (iii) Person acquires a portion of NABI’s business which conducted, at any time, any activities related to the Licensed Product (such Person or Affiliate described in
clauses (i), (ii) or (iii) being referred to as the “Affected Person”), and such Affected Person has or is developing a Competitive Product, then to ensure NABI’s compliance with this Section 6.1, (x) the
NABI personnel who had access to Confidential Information of FRESENIUS may not become involved in the activities of such Affected Person in respect of its Competitive Product, and (y) all Confidential Information of FRESENIUS that shall remain
in NABI’s possession or control, if any, shall be segregated and walled off from access by the personnel of such Affected Person involved in its activities in respect of such Competitive Product. 
 C. The provisions of this Section 6 shall survive the expiration or termination of this Agreement. 
  

	 	6.2	Confidential Treatment 

 Each party shall
seek reasonable confidential treatment for the terms and conditions of this Agreement to the extent permitted by the Securities and Exchange Commission (the “SEC”) and any other governmental agency or self-regulatory organization to
which such party provides a copy of, or discloses the terms of, this Agreement. Prior to seeking confidential treatment from the SEC or any other governmental agency or self-regulatory organization for any such document, the party required to make
such disclosure shall consult with the other party if practicable, and provide them with a reasonable opportunity to request the exclusion of specified provisions and any request by it for confidential treatment. 
  

	 	6.3	Exclusions 

 A. Nothing contained in this Agreement shall
preclude FRESENIUS or NABI from utilizing Confidential Information of the other party as may be necessary in obtaining governmental approvals for any purpose permitted under this Agreement. 
 B. In the event that Confidential Information of the other party is required by law or government regulations to be disclosed, the party disclosing such
Confidential Information shall, to the extent it may legally do so, timely: 
 (i) inform the original disclosing party
hereunder of such requirement; 
 (ii) use reasonable efforts to limit such disclosure and maintain confidentiality to the
extent possible; and 
 (iii) permit the original disclosing party to attempt to limit such disclosure by appropriate legal
means. 
  

 15 

 C. Anything herein to the contrary notwithstanding, nothing in this Agreement shall be construed to grant
NABI (or any party acquiring Confidential Information from NABI) any right to prosecute a patent application for any aspect of Licensed Product. 
  

	 	6.4	Public Announcements 

 A. Neither party shall make any
public announcement concerning this Agreement, nor make any public statement which includes the name of the other party or any of its Affiliates, or otherwise use the name of the other party or any of its Affiliates in any public statement or
document without the written consent of the other party, which consent shall not be withheld or delayed unreasonably except: 
 (i) as may be required by applicable accounting rules or standards, law, judicial order or the rules of any stock exchange where the stock or securities of the disclosing party are listed to the extent that the disclosing party is required
to observe such rules, or 
 (ii) in a subsequent public statement or document regarding this Agreement which has already
been approved by the other party. 
 B. As promptly as possible after the execution and delivery of this Agreement, the parties shall prepare
a mutually acceptable statement for purposes of dissemination to the clinical research centers and others who are currently engaged in the lung Study. 
  

	 	7.	INDEMNIFICATION AND INSURANCE 

  

	 	7.1	Indemnification by FRESENIUS 

 Subject to
the terms and conditions of this Section 7, from and after the Effective Date, FRESENIUS shall indemnify, defend and hold harmless NABI and its Affiliates, and each of its and their respective officers, directors, employees, agents and
representatives (the “NABI Indemnitees”) in respect of any and all liabilities, obligations, judgments, interest, losses, assessments, damages, fines, fees, penalties, costs and expenses (including without limitation reasonable
attorneys’ fees and expenses of investigating and defending claims, lawsuits, complaints, actions or other pending or threatened litigation) (collectively, “Damages”) incurred or suffered by any of the NABI Indemnitees
resulting from or attributable to: 
 A. any breach of any representation or warranty of FRESENIUS contained in this Agreement; 
 B. any failure by FRESENIUS to have performed or observed Section 9 of the March 30 Agreement prior to the Effective Date; 
 C. any failure by FRESENIUS to perform or observe any covenant or agreement required to be performed or observed by FRESENIUS as provided in this
Agreement; 
 D. any Damages to a third party attributable to the action or inaction of FRESENIUS in connection with any Study after the End
Date; 
  

 16 

 E. any defect, latent or otherwise, in any Licensed Product delivered to NABI before or after the
Effective Date (but only to the extent used in connection with the Studies), including without limitation any defect occurring as a result of the manufacturing, handling, processing, storage or transportation of Licensed Product prior to delivery to
NABI; and 
 F. any claim that the development, manufacture, sale or use of a Licensed Product by NABI pursuant to the March 30
Agreement or this Agreement infringed or infringes the intellectual property rights of a third party or misappropriated or misappropriates the trade secrets of a third party. 
  

	 	7.2	Indemnification by NABI 

 Subject to the
terms and conditions of this Section 7, from and after the date hereof, NABI shall indemnify, defend and hold harmless FRESENIUS and its Affiliates, and each of its and their respective officers, directors, employees, agents and representatives
(the “FRESENIUS Indemnitees”) in respect of any and all Damages incurred or suffered by any of the FRESENIUS Indemnitees resulting from or attributable to: 
 A. any breach of any representation or warranty of NABI contained in this Agreement; 
 B. any failure by NABI to have performed or observed Section 9 of the March 30 Agreement prior to the Effective Date; 
 C. any failure by NABI to perform or observe any covenant or agreement required to be performed or observed by NABI as provided in this Agreement;

 D. any Damages to a third party attributable to the action or inaction of NABI in connection with any Study prior to the End Date; or

 E. any defect in any Licensed Product (but only to the extent used in connection with the Studies) occurring as a result of the handling,
processing, storage or transportation of the Licensed Product after delivery to NABI before or after the Effective Date. 
  

	 	7.3	Third Party Claims 

 A. All claims for indemnification made
under this Agreement resulting from, related to or arising out of a third-party claim against an Indemnified Party shall be made in accordance with the following procedures. 
 (i) A Person entitled to indemnification under this Section 7 (an “Indemnified Party”) shall give prompt written
notification to the Person from whom indemnification is sought (the “Indemnifying Party”) of the commencement of any action, suit or proceeding relating to a third-party claim (a “Third Party Claim”) for which
indemnification may be sought or, if earlier, upon the assertion in writing of any such claim by a third party; provided, however, that the failure so to notify the Indemnifying Party promptly or at all shall not relieve the Indemnifying Party of
any liability or obligation it may have to the Indemnified Party hereunder except to the extent of actual prejudice caused by such 

  

 17 

 
failure. Such written notification shall include a description in reasonable detail (to the extent known by the Indemnified Party) of the facts constituting
the basis for such Third Party Claim and the amount of the Damages claimed. Within twenty-five (25) days after delivery of such written notification, the Indemnifying Party may, by written notice thereof to the Indemnified Party, assume control
of the defense of such action, suit, proceeding or claim with counsel reasonably satisfactory to the Indemnified Party. Notwithstanding the foregoing, the Indemnifying Party may not assume the defense of any Third Party Claim for equitable or other
non-monetary relief that would materially affect the ongoing operations of the business of the Indemnified Party. 
 (ii) The
party not controlling such defense may participate therein at its own expense; provided that if the Indemnifying Party assumes control of such defense and the Indemnified Party reasonably concludes, based on advice from counsel, that the
Indemnifying Party and the Indemnified Party have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnified Party may assume or retain control of such action, suit, proceeding or claim and the reasonable fees and
expenses of counsel to the Indemnified Party solely in connection therewith shall be considered “Damages” for the purposes of this Agreement; provided, however, that in no event shall the Indemnifying Party be responsible for the fees and
expenses of more than one counsel for all Indemnified Parties. The party controlling such defense shall keep the other party advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations
made by the other party with respect thereto. 
 (iii) The Indemnifying Party shall not agree to any settlement of any Third
Party Claim without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. The Indemnifying Party shall not agree to any settlement of any Third Party Claim that does not include a complete
release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party without the prior written consent of the Indemnified Party, which consent shall not be unreasonably
withheld or delayed. 
  

	 	7.4	Procedure for Other Claims 

 An Indemnified
Party wishing to assert a non-Third Party Claim for indemnification under this Section 7 shall deliver to the Indemnifying Party a written notice (a “Claim Notice”) which contains (i) a description and the amount (the
“Claimed Amount”) of any Damages incurred by the Indemnified Party, (ii) a statement that the Indemnified Party is entitled to indemnification under this Section 7 and a reasonable explanation of the basis therefor, and
(iii) a demand for payment of such Claimed Amount. Within twenty-five (25) days after delivery of a Claim Notice, the Indemnifying Party shall deliver to the Indemnified Party a written response in which the Indemnifying Party shall:
(x) agree that the Indemnified Party is entitled to 

  

 18 

 
receive all of the Claimed Amount (in which case such response shall be accompanied by a payment by the Indemnifying Party to the Indemnified Party of the
Claimed Amount, by check or by wire transfer), (y) agree that the Indemnified Party is entitled to receive part, but not all, of the Claimed Amount (the “Agreed Amount”) (in which case such response shall be accompanied by a
payment by the Indemnifying Party to the Indemnified Party of the Agreed Amount, by check or by wire transfer ), or (z) contest that the Indemnified Party is entitled to receive any of the Claimed Amount. If the Indemnifying Party in such
response contests the payment of all or part of the Claimed Amount, the Indemnifying Party and the Indemnified Party shall use good faith efforts to resolve such dispute. If such dispute is not resolved within sixty (60) days following the
delivery by the Indemnifying Party of such response, the Indemnifying Party and the Indemnified Party shall each have the right to litigate such dispute in accordance with the provisions of Section 8.1. 
  

	 	7.5	Product Liability Insurance 

 Each party
shall maintain through the End Date, and for at least six (6) years thereafter, general liability insurance with an internationally reputable, credit-worthy, unaffiliated insurance company, which insurance shall include product liability
coverage and shall be in amounts and of a type customarily maintained by companies similarly situated, provided that such insurance shall provide at least Ten Million US Dollars ($10,000,000) in coverage per occurrence unless such insurance is
unavailable in the insurance market. On or prior to the End Date, each party shall deliver to the other evidence of its insurance. 
  

	 	7.6	Special, Indirect or Like Damages 

 IN NO
EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY SIMILAR ECONOMIC LOSS SUCH AS LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, PROVIDED, HOWEVER, THAT THIS
SECTION 7.6 SHALL NOT APPLY (A) IN RESPECT OF A CLAIM BY FRESENIUS THAT NABI OR ONE OF ITS AFFILIATES HAS BREACHED THE PROVISIONS OF SECTIONS 6.1 AND 6.2, (B) TO THE EXTENT THAT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID BY AN INDEMNIFIED
PARTY TO A THIRD PARTY AS PART OF A THIRD PARTY CLAIM FOR WHICH INDEMNIFICATION MAY BE OWING BY THE INDEMNIFYING PARTY HEREUNDER, AND (C) IN RESPECT OF A CLAIM ASSERTING GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. 
  

	 	7.7	Specific Performance 

 The parties
acknowledge that the obligations set forth in Sections 2, 3 and 6 are necessary for the protection of the parties and each party agrees that any breach thereof shall cause the affected party irreparable damage, that the affected party’s
remedies at law in the event of such breach would be inadequate, and that, accordingly, the affected party shall be entitled to equitable relief including the issuance by a court of competent jurisdiction of an injunction in favor of the affected
party. The foregoing provision shall not constitute a waiver or election of any other remedies any party may have in law or in equity subject, however, to the limitations contained in this Agreement. 
  

 19 

	 	8.	MISCELLANEOUS 

  

	 	8.1	Jurisdiction and Dispute Resolution 

 A. This Agreement
shall be governed by and construed in accordance with the laws of the State of New York, without reference to the conflict of law principles thereof (except that § 5-1401 of the New York General Obligations Law shall apply). For the avoidance
of doubt, the parties agree that the UN Convention on the International Sale of Goods shall not be applicable to this Agreement. 
 B. Any
action, litigation or suit (collectively, a “Proceeding”) arising out of or relating to this Agreement shall be brought in the courts of the State and County of New York, or, if it has or can acquire subject matter jurisdiction, in
the United States District Court for the Southern District of New York, and each of the parties irrevocably submits to the personal and exclusive jurisdiction of each such court in any such Proceeding, waives any objection it may now or hereafter
have to personal jurisdiction, venue or to convenience of forum in any such Proceeding, agrees that all claims in respect of the Proceeding shall be heard and determined only in any such court, and agrees not to bring any Proceeding arising out of
or relating to this Agreement in any other court. The parties agree that either or both of them may file a copy of this Section with any court in any such Proceeding as written evidence of the knowing, voluntary and bargained agreement between the
parties irrevocably to waive any objections they might have based on personal jurisdiction, improper venue or convenience of forum. Process in any such Proceeding may be served on any party anywhere in the world, and each party agrees that service
of process by an overnight delivery service is sufficient and enforceable. In any action or proceeding to enforce rights under this Agreement, the prevailing party will be entitled to recover reasonable costs and attorneys’ fees. The parties
hereby waive the right to a trial by jury in any Proceeding brought against the other with respect to this Agreement or their respective performance hereunder. 
 C. If FRESENIUS shall allege in writing that NABI has breached its obligations under Section 6.1, then NABI agrees to make available to FRESENIUS such of its relevant documents for inspection, and such if its
personnel for interviews, as shall be reasonably requested by FRESENIUS to determine whether such breach has occurred. If FRESENIUS shall not be satisfied with NABI’s performance of its commitment in this Section 8.1C, then FRESENIUS’
sole remedy shall be to initiate a Proceeding in accordance with Section 8.1B alleging a breach of Section 6.1. 
  

	 	8.2	Force Majeure 

 A. Neither party shall be held in breach of
this Agreement for failure to perform any of its obligations hereunder (except the payment of money) and the time required for performance shall be extended for a period equal to the period of such delay provided that such delay has been caused by
or is a result of circumstances beyond the reasonable control of the party so affected, including without limitation any acts of God; acts of the public enemy; civil strife; wars declared or undeclared; embargoes; labor disputes; including strikes,
lockouts, job actions or boycotts; fires; explosion; and floods. A governmental or regulatory inspection or order directed at either party shall not be considered to be a force majeure event for the purposes of this Agreement. 
  

 20 

 B. The party so affected by a force majeure event within the scope of this Agreement shall: 

(i) give prompt written notice to the other party of the nature and date of commencement of the force majeure event and its expected
duration; and 
 (ii) use commercially reasonable efforts to relieve the effect of such cause as rapidly as possible.

  

	 	8.3	Relationship of the Parties 

 The
relationship of the parties under this Agreement is that of independent contractors. Nothing contained in this Agreement shall be construed so as to constitute the parties as joint venturers or agents of the other. Neither party nor any of its
Affiliates has any express or implied right or authority under this Agreement to assume or create any obligations or make any representations or warranties on behalf of or in the name of the other party or its Affiliates. 
  

	 	8.4	Assignment 

 A. By FRESENIUS 
 (1) Subject to compliance with subparagraph (2) below, FRESENIUS may assign its rights and obligations under this Agreement to:
(i) any entity which is included with FRESENIUS in a consolidated financial statement prepared in accordance with generally accepted financial standards applicable to FRESENIUS; or (ii) a Person which acquires all or substantially all of
the stock or assets of FRESENIUS. 
 (2) If FRESENIUS assigns its rights and obligations under this Agreement in compliance
with the foregoing subparagraph (1), FRESENIUS shall promptly notify NABI of any such assignment. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 
 (3) No assignment shall relieve FRESENIUS of responsibility for the performance of any obligation which such party may have incurred
hereunder prior to the assignment. 
 (4) No assignment by FRESENIUS pursuant to clause (i) of subparagraph
(1) above shall relieve FRESENIUS of any responsibility for non-performance by its assignee Affiliate of any obligation assigned. 
 B. By NABI 
 (1) Subject to compliance with subparagraph (2) below, NABI may assign its
rights and obligations under this Agreement to (i) any entity which is included with NABI in a consolidated financial statement prepared in 

  

 21 

 
accordance with generally accepted financial standards applicable to NABI or (ii) a Person which acquires all or substantially all of the stock or
assets of NABI provided, however, any such Person shall in all events be bound by the provisions of Section 6.1; 
 (2)
If NABI assigns its rights and obligations under this Agreement in compliance with the foregoing subparagraph (1), NABI shall promptly notify FRESENIUS of any such assignment. Any permitted assignee shall assume all obligations of its assignor under
this Agreement. 
 (3) No assignment shall relieve NABI of responsibility for the performance of any obligation which such
party may have incurred hereunder prior to the assignment. 
 (4) No assignment by NABI pursuant to clause (i) of
subparagraph (1) above shall relieve NABI of any responsibility for non-performance by its assignee Affiliate of any obligation assigned. 
  

	 	8.5	Binding Effect 

 This Agreement shall be
finding upon and inure to the benefit of each of the parties and its successors and permitted assigns. 
  

	 	8.6	Entire Agreement 

 This Agreement,
including the Schedules, which are incorporated herein by reference, the Escrow Agreement and all documents delivered in connection therewith, collectively set forth the entire understanding of the parties concerning the subject matter hereof and
supersede all written or oral prior agreements or understanding with respect thereto including the March 30 Agreement. 
  

	 	8.7	Compliance with Laws 

 In performing this
Agreement, each party shall comply with all applicable treaties, laws and regulations and shall not be required to perform or omit to perform any act required or permitted under this Agreement if such performance or omission would violate the
provisions of any such treaty, law or regulation. Without limiting the generality of its obligation to comply with applicable laws, NABI represents that it and its employees, directors, officers, and agents have at all times in connection with the
Studies complied, and through the End Date will comply, in all material respects with respect to the Licensed Product with applicable laws and regulations regarding healthcare fraud and abuse, kickbacks and bribes, and integrity in research.

  

 22 

	 	8.8	Notices 

 All notices hereunder shall be in
writing and shall be: (a) delivered personally; (b) mailed by registered or certified mail, postage prepaid; (c) sent by overnight courier, or (d) sent by facsimile or express mail to the following addresses or the respective
parties. 
 If to NABI: 
 Nabi Biopharmaceuticals 
 5800 Park of Commerce Blvd. NW 
 Boca Raton, FL 33487 
 Facsimile Number: 561-989-5890 
  

					
		 	With a copy to:	  	NABI’s General Counsel
		 		  	at the same address.
			
		 	And a copy to:	  	NABI Biopharmaceuticals
		 		  	12276 Wilkins Avenue
		 		  	Rockville, MD 20852
		 		  	Attention: President
		 		  	Facsimile Number: 301-770-0093

 If to FRESENIUS: 
 FRESENIUS BIOTECH GmbH 
 President 
 Borkenberg 14 
 Oberursel Germany 
 Facsimile Number: 49-6172-608-2680 
  

					
		 	With copy to:	  	FRESENIUS AG
		 		  	Legal Department
		 		  	D-61352 Bad Homburg
		 		  	Germany
		 		  	Facsimile Number: 49-6172-608-2251
			
		 	With a copy to:	  	Aydin S. Caginalp, Esq.
		 		  	Manatt, Phelps, Phillips, LLP
		 		  	7 Times Square
		 		  	New York, New York 10036
		 		  	acaginalp@manatt.com

 Notices shall be effective upon receipt. 
  

	 	8.9	Severability 

 If any provision of this
Agreement for any reason shall be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if
such term or provision, to the extent the same shall have been held to be invalid illegal or unenforceable, had never been contained herein. 
  

 23 

	 	8.10	Waiver of Modification of Agreement 

 No
waiver of modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both parties. Failure by either party to enforce any of its rights under this Agreement shall not be construed
as a waiver of such rights nor shall a waiver by either party in one of more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
  

	 	8.11	Headings 

 The captions in this Agreements
are inserted for convenience only and are not a part hereof. 
  

	 	8.12	Counterparts 

 This Agreement may be
executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. 
  

	 	8.13	Further Assurances 

 NABI shall, from
time to time, at the request of FRESENIUS, execute, acknowledge, and deliver to FRESENIUS such instruments of conveyance and transfer and execute and deliver such other documents, certifications, and further assurances as FRESENIUS may
reasonably require in order to effectuate the intent of this Agreement or to better enable FRESENIUS to pay, perform or satisfy any of the Assigned Contracts. Each party shall bear its own costs and expenses in compliance with this
Section 8.13. 
 IN WITNESS WHEREOF, each party has caused this Agreement to be executed by its duly authorized officer on the date below written.

  

									
	NABI BIOPHARMACEUTICALS	 		 	FRESENIUS BIOTECH GmbH
					
	By:	 	  
	 		 	By:	 	  

	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	
		 		 		 	Title:	 	

  

 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]